AEGIRBIO Receives Milestone Payment under RadX NIH

AegirBio AB, a forefront leader in saliva-based diagnostics solutions, announces today the company has received its inaugural milestone-based payment of USD 148,026 under the RadX NIH program. This milestone validates our unwavering dedication to pioneering research and development.

"At AegirBio, we are committed to pushing the boundaries of innovation and fostering positive change in healthcare. This payment from RadX NIH reflects the tireless efforts of our team," said Marco Witteveen, CEO of AegirBio.

As we celebrate this milestone, our commitment to advancing with RadX remains unwavering. With ongoing support from initiatives like RadX NIH and the expertise of our talented team, we are positioned to drive significant progress and make meaningful contributions to the field.

For additional information, please contact::

Marco Witteveen, CEO, Aegirbio AB

Email: ir@aegirbio.com

About Aegirbio

AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com

The company's Certified Adviser is Eminova Fondkomission AB; info@eminova.se